An unusual case of massive subcutaneous chest wall haemorrhage with enoxaparin

Abstract

Enoxaparin is used in the treatment of acute coronary syndromes and offers improved outcome in the composite endpoint of death, myocardial infarction and major bleeding when compared with unfractionated heparin (UFH). Our report describes a rare case of massive life-threatening subcutaneous chest wall haemorrhage, distant to the injection site. Clinicians should be aware of atypical presentations of haemorrhage when using combination antiplatelet and antithrombotic therapy.

Keywords::

• Enoxaparin
• clexane
• bleeding
• subcutaneous
• haemorrhage
• haematoma
• acute coronary syndrome, atypical, low-molecular weight heparin

Acknowledgements

The authors thank the patient described in the case who provided full written consent for submission of the case report, the medical and cardiology teams involved in his care and Dr Qasim and Dr Soo as supervising Consultants.

Declaration of interest: The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.